Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Doutor Nichires Holdings Co., Ltd. ( (JP:3087) ) has provided an announcement.
DOUTOR·NICHIRES Holdings reported consolidated net sales of ¥119.7 billion for the nine months ended November 30, 2025, up 6.5% year on year, while operating profit was almost flat at ¥8.0 billion and profit attributable to owners of parent edged down 0.6% to ¥5.75 billion, indicating that higher sales did not fully translate into bottom-line growth. The company’s equity ratio remained solid at 76.1%, and it continues to return cash to shareholders, raising the interim dividend to ¥27 per share and forecasting a full-year dividend of ¥56, while maintaining its full-year outlook for fiscal 2026 with net sales of ¥154.5 billion and a double‑digit increase in operating profit, suggesting confidence in earnings resilience despite margin pressure and ongoing share buybacks that have reduced shares outstanding and increased treasury stock.
The most recent analyst rating on (JP:3087) stock is a Hold with a Yen2688.00 price target. To see the full list of analyst forecasts on Doutor Nichires Holdings Co., Ltd. stock, see the JP:3087 Stock Forecast page.
More about Doutor Nichires Holdings Co., Ltd.
DOUTOR·NICHIRES Holdings Co., Ltd. is a Japan-based company listed on the Tokyo Stock Exchange, operating in the food and beverage sector through coffee shop and related retail businesses. The group focuses on domestic consumers, leveraging well-known café brands and associated food services to drive stable, recurring revenue in the Japanese market.
Average Trading Volume: 109,491
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen116.4B
See more data about 3087 stock on TipRanks’ Stock Analysis page.